Press release
Myelodysplastic Syndromes Market Key Country Analysis: Otsuka Holdings Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD., Lupin, Takeda Pharmaceutical Company Limited
Global myelodysplastic syndromes market is rising gradually with a healthy CAGR of 11.09% in the forecast period of 2019-2026. Increasing geriatric population, growing awareness about the diseases and improving healthcare expenditure are some major drivers for the market growth.Some of the key players from the complete study are Astex Pharmaceuticals, Otsuka Holdings Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD., Lupin, Takeda Pharmaceutical Company Limited, Onconova Therapeutics, Helsinn Healthcare SA, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., MEI Pharma Inc., Aprea Therapeutics, Boston Biomedical, AbbVie Inc., Acceleron Pharma, Inc., BerGenBio ASA, CELGENE CORPORATION, Eisai Co., Ltd. among others.
Request Sample of Global Myelodysplastic Syndromes Market 2019 Forecast to 2026 @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-myelodysplastic-syndromes-market
Market Definition:
Myelodysplastic syndromes are a rare group of hematological diseases that are caused by formation of abnormal blood-forming cells in the bone marrow. It occurs due to the mutation of one or more genes which controls the development of blood cells. These are also referred as bone marrow failure disorder. In myelodysplastic syndrome the bone marrow fails to produce healthy red blood cells, white blood cells and or platelets. The most common symptoms of myelodysplastic syndromes are fatigue, weakness, shortness of breath, bone pain and others. The symptoms and severity of MDS varies from person to person.
The prevalence of MSD is estimated to be approximately 22 to 45 cases per 100,000 people over the age of 70. This disease occurs slightly more in males than females. MSD can develop in any age group but it mostly affects population over the age of 60 years.
Market Drivers
Increasing geriatric population which has a tendency of getting effected with myelodysplastic syndrome acts as a market driver
Technological advancements in the sequencing technologies also drives this market growth
Government initiatives for research and development of target specific therapies and favorable reimbursement policies will also boost this market growth in the forecast period
Growing awareness about the diseases associated with MDS is expected to drive the market growth
Market Restraints
High cost therapies of myelodysplastic syndromes restricts the market growth
Novel treatment options due to the complexity and heterogeneity of can hamper the market growth
Order a Copy of This Research Report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-myelodysplastic-syndromes-market
Segmentation:
By Type
Myelodysplastic Syndrome with Unilineage Dysplasia
Myelodysplastic Syndrome with Multilineage Dysplasia
Myelodysplastic Syndrome with Ring Sideroblasts
Others
By Diagnosis
Complete Blood Count
Bone Marrow Aspiration and Biopsy
Others
By Treatment
Medication
Blood Transfusion
Bone Marrow Transplantation
Others
By Route of Administration
Oral
Injectable
Others
By End Users
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channels
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Others
By Geography
North America
U.S.
Canada
Mexico
South America
Brazil
Rest of South America
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Turkey
Belgium
Netherlands
Switzerland
Rest of Europe
Asia-Pacific
Japan
China
South Korea
India
Australia
Singapore
Thailand
Malaysia
Indonesia
Philippines
Rest of Asia Pacific
Middle East & Africa
South Africa
Rest of Middle East & Africa
Key Developments in the Market:
In September 2019, Astex Pharmaceuticals received the Orphan Drug designation for the U. S. FDA for ASTX727, a novel oral hypomethylating agent used for treatment of patients with Myelodysplastic Syndromes (including chronic myelomonocytic leukemia). Astex Pharmaceuticals is a subsidiary of Otsuka Holdings Co., Ltd. and TAIHO PHARMACEUTICAL CO., LTD. The grant of this designation to the drug will provide a seven year market exclusivity in the United States, to the company
In November 2018, Lupin received marketing approval from the U. S. FDA for Decitabine, the generic version of dacogen for treatment of patients with myelodysplastic syndrome. This productis available in injectable dosage form and has similar efficacy to dacogen with treated and untreated, de novo and secondary MDS. This approval provides the marketing grant of Otsuka Pharmaceutical Co. Ltd.’s dacogen and increase the market size of Lupin
Competitive Analysis:
Global myelodysplastic syndromes market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of myelodysplastic syndromes market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Reasons to Purchase this Report
Current and future of global myelodysplastic syndromes market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
Regions/Countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players
View Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-myelodysplastic-syndromes-market
Contact:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email: Corporatesales@databridgemarketresearch.com
About Data Bridge Market Research
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myelodysplastic Syndromes Market Key Country Analysis: Otsuka Holdings Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD., Lupin, Takeda Pharmaceutical Company Limited here
News-ID: 2148311 • Views: …
More Releases from Data Bridge Market Research

Water Treatment System Market: Sustaining the Future of Clean Water
Introduction
Understanding Water Treatment Systems
Water treatment systems are designed to purify and disinfect water for various uses-drinking, industrial processes, irrigation, and wastewater reuse. These systems eliminate contaminants such as bacteria, viruses, heavy metals, chemicals, and particulates, making water safe and sustainable for consumption and use.
Importance in Global Sustainability
Clean water is essential to life and industrial progress. With growing water demand and pollution, water treatment systems are now critical infrastructure across the…

Veterinary X-Ray Market Size, Analysis, Scope, Demand, Opportunities, Statistics
According to Data Bridge Market Research The global Veterinary X-Ray market size was valued at USD 915.19 million in 2024 and is projected to reach USD 1576.00 million by 2032, with a CAGR of 7.03 % during the forecast period of 2025 to 2032.
With increasing globalization and digital disruption, the Equine X-Ray Solutions Market is expanding across multiple industries, . Market research data indicates that businesses in the Companion Animal…

Veterinary X-Ray Market Size, Analysis, Scope, Demand, Opportunities, Statistics
According to Data Bridge Market Research The global Veterinary X-Ray market size was valued at USD 915.19 million in 2024 and is projected to reach USD 1576.00 million by 2032, with a CAGR of 7.03 % during the forecast period of 2025 to 2032.
With increasing globalization and digital disruption, the Equine X-Ray Solutions Market is expanding across multiple industries, . Market research data indicates that businesses in the Companion Animal…

Veterinary X-Ray Market Size, Analysis, Scope, Demand, Opportunities, Statistics
According to Data Bridge Market Research The global Veterinary X-Ray market size was valued at USD 915.19 million in 2024 and is projected to reach USD 1576.00 million by 2032, with a CAGR of 7.03 % during the forecast period of 2025 to 2032.
With increasing globalization and digital disruption, the Equine X-Ray Solutions Market is expanding across multiple industries, . Market research data indicates that businesses in the Companion Animal…
More Releases for Myelodysplastic
Myelodysplastic Syndrome Drugs Market Research and Treatment Advancements
On April 11, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Myelodysplastic Syndrome Drugs Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands…
Prominent Myelodysplastic Syndrome (MDS) Drugs Market Trend for 2025: Innovative …
What Are the Projected Growth and Market Size Trends for the Myelodysplastic Syndrome (MDS) Drugs Market?
The myelodysplastic syndrome (MDS) drugs market has expanded steadily in recent years. It is projected to increase from $3.47 billion in 2024 to $3.73 billion in 2025, reflecting a CAGR of 7.5%. The past growth can be attributed to the aging population, advancements in targeted therapies, ongoing clinical trials, and increased awareness.
The myelodysplastic syndrome (MDS)…
Myelodysplastic Syndrome (MDS) Treatment Market Insights, Forecast to 2031
"Myelodysplastic Syndrome (MDS) Treatment Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Myelodysplastic Syndrome (MDS) Treatment market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Myelodysplastic Syndrome (MDS) Treatment industry, providing stakeholders…
Myelodysplastic Syndrome Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2024" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelodysplastic Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic…
Myelodysplastic Syndrome Market Size, Epidemiology, Analysis & Trends 2023-2033
Market Overview:
The myelodysplastic syndrome market is expected to exhibit a CAGR of 6.51% during 2023-2033. The myelodysplastic syndrome market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the…
Myelodysplastic Syndrome Market to see Huge Growth by 2029
Myelodysplastic Syndrome Market was valued at USD 2.8 billion in 2022 and is expected to grow at a CAGR of 10% between 2023 and 2029. Important changes in the business allow key players to attain larger profits. This Myelodysplastic Syndrome Market study report is the best way to make changes with the help of entire market condition and metrics provided here. These metrics also allow getting ahead in the industry.…